Smirnov A A, Dorogun B N, Dobrovol'skiĭ A B, Titaeva E V, Pomerantsev E V
Kardiologiia. 1988 Nov;28(11):40-6.
Variation in major coagulation parameters was assessed in 87 patients with acute myocardial infarction, treated with streptokinase and/or heparin under angiographic control. Streptokinase treatment was associated with a drop in plasma fibrinogen, plasminogen and alpha 2-antiplasmin, and an increase in serum fibrin/fibrinogen degradation products. The magnitude of coagulation shifts was greater in case of intravenous streptokinase infusion (1,000,000 units over 60 min), as compared to intracoronary streptokinase administration in lower doses (120,000-180,000 units over 60-90 min). In all patients with regained coronary flow, fibrinogen, plasminogen and alpha 2-antiplasmin levels began to decline significantly earlier and/or became normal significantly later, as compared to patients with persisting coronary occlusion. The rates and severity of hemorrhagic complications were basically similar in intravenous and intracoronary routes of administration, in spite of different doses and magnitude of coagulation shifts.
在87例急性心肌梗死患者中评估了主要凝血参数的变化,这些患者在血管造影控制下接受链激酶和/或肝素治疗。链激酶治疗与血浆纤维蛋白原、纤溶酶原和α2 -抗纤溶酶水平下降以及血清纤维蛋白/纤维蛋白原降解产物增加有关。与较低剂量冠状动脉内给予链激酶(60 - 90分钟内给予120,000 - 180,000单位)相比,静脉输注链激酶(60分钟内给予1,000,000单位)时凝血变化幅度更大。与冠状动脉持续闭塞的患者相比,在所有冠状动脉血流恢复的患者中,纤维蛋白原、纤溶酶原和α2 -抗纤溶酶水平显著更早开始下降和/或显著更晚恢复正常。尽管凝血变化的剂量和幅度不同,但静脉和冠状动脉给药途径的出血并发症发生率和严重程度基本相似。